Market capitalization | JPY2.81t |
Enterprise Value | JPY3.56t |
P/E (TTM) P/E ratio | 51.40 |
EV/FCF (TTM) EV/FCF | 22.03 |
EV/Sales (TTM) EV/Sales | 2.01 |
P/S ratio (TTM) P/S ratio | 1.59 |
P/B ratio (TTM) P/B ratio | 1.84 |
Dividend yield | 4.71% |
Last dividend (FY25) | JPY74.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
15 Analysts have issued a Astellas Pharma forecast:
15 Analysts have issued a Astellas Pharma forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,772,155 1,772,155 |
16%
16%
|
|
Gross Profit | 1,314,886 1,314,886 |
10%
10%
|
|
EBITDA | 387,169 387,169 |
10%
10%
|
EBIT (Operating Income) EBIT | 191,257 191,257 |
21%
21%
|
Net Profit | 54,746 54,746 |
61%
61%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Naoki Okamura |
Employees | 14,754 |
Founded | 1923 |
Website | www.astellas.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.